Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

3.
4.

Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.

d'Amico A.

Radiol Med. 2015 Apr;120(4):345-51. doi: 10.1007/s11547-014-0446-4. Epub 2014 Aug 26. Review.

5.

What does positron emission tomography offer oncology?

Anderson H, Price P.

Eur J Cancer. 2000 Oct;36(16):2028-35. Review.

PMID:
11044638
6.

FDG uptake, tumour characteristics and response to therapy: a review.

Smith TA.

Nucl Med Commun. 1998 Feb;19(2):97-105. Review.

PMID:
9548192
7.

[Monitoring of response to neoadjuvant therapy by positron emission tomography (PET)].

Ott K, Weber WA, Fink U, Schwaiger M, Siewert JR.

Chirurg. 2001 Sep;72(9):1003-9. Review. German.

PMID:
11594268
8.
9.

[18F FDG PET- applications in oncology].

R─âileanu I, Rusu V, Stef─ânescu C, Cinotti L.

Rev Med Chir Soc Med Nat Iasi. 2001 Oct-Dec;105(4):638-45. Review. Romanian.

PMID:
12092212
10.

Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?

Anderson H, Singh N, Miles K.

Cancer Imaging. 2010 Oct 4;10 Spec no A:S68-72. doi: 10.1102/1470-7330.2010.9088. Review.

11.

A shifting landscape: what will be next FDG in PET oncology?

Inoue T, Oriuchi N, Tomiyoshi K, Endo K.

Ann Nucl Med. 2002 Feb;16(1):1-9. Review.

PMID:
11922202
12.

Use of PET for monitoring cancer therapy and for predicting outcome.

Weber WA.

J Nucl Med. 2005 Jun;46(6):983-95. Review.

13.

PET scan imaging in oncology.

Jerusalem G, Hustinx R, Beguin Y, Fillet G.

Eur J Cancer. 2003 Jul;39(11):1525-34. Review.

PMID:
12855258
14.
15.

[Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personalization].

Bonardel G, Vedrine L, Aupee O, Gontier E, Le Garlantezec P, Soret M, Foehrenbach H.

Bull Cancer. 2009 Feb;96(2):213-26. doi: 10.1684/bdc.2008.0816. Review. French.

16.

Positron emission tomography in oncology.

Leskinen-Kallio S.

Clin Physiol. 1994 May;14(3):329-35. Review.

PMID:
8026150
17.

[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Technical bases and regulatory principles].

Bourguet P; Groupe de Travail SOR.

Bull Cancer. 2003 Feb;90 Spec No:S18-22. Review. French. No abstract available.

18.

Clinical applications of 18F-FDG PET/CT in monitoring anti-cancer therapies.

Wu P, Zhang Y, Sun Y, Shi X, Li F, Zhu Z.

Curr Pharm Biotechnol. 2013;14(7):658-68. Review.

PMID:
24372234
19.

Implications of PET based molecular imaging on the current and future practice of medicine.

Alavi A, Kung JW, Zhuang H.

Semin Nucl Med. 2004 Jan;34(1):56-69. Review.

PMID:
14735459
20.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D; National Cancer Institute.

J Nucl Med. 2006 Jun;47(6):1059-66. No abstract available.

Supplemental Content

Support Center